8 data-"https:" "https:" "https:" "https:" "https:" "https:" "https:" "The University of Gothenburg" uni jobs at Center for Biologics Evaluation and Research (CBER)

FDA Computational and Experimental Assessment of Engineered Biotherapeutics: Safety and Regulatory Considerations of Synonymous Gene Recoding

Center for Biologics Evaluation and Research (CBER) | Silver Spring, Maryland | United States | about 15 hours ago

Biol, 169718 (2026). https://doi.org:10.1016/j.jmb.2026.169718 Katneni, U.K., Liss, A., Holcomb, D., Katagiri, N., Hunt, R.C., Bar, H., Ismail, A., Komar, A.A. and Kimchi-Sarfaty, C.: Splicing

FDA Research Opportunity - Immune Responses to Influenza Vaccines

Center for Biologics Evaluation and Research (CBER) | Silver Spring, Maryland | United States | about 16 hours ago

multiple techniques including multiplex assays, virus neutralization, Plasmon Surface Resonance machines, protein production, and more Learn skills in data analysis software including statistical software

FDA Research Opportunity in Developing Methods for Efficient Gene Editing in Hematopoietic Stem Cells (HSCs)

Center for Biologics Evaluation and Research (CBER) | Silver Spring, Maryland | United States | about 16 hours ago

Residents (LPR), and foreign nationals. Non-U.S. citizen applicants should refer to the Guidelines for Non-U.S. Citizens Details page  of the program website for information about the valid immigration

FDA Focus Towards More Efficient Factor VIII Drug Products to Improve the Treatment of Hemophilia A

Center for Biologics Evaluation and Research (CBER) | Silver Spring, Maryland | United States | about 16 hours ago

obligation to protect and not to further disclose or use non-public information.

FDA Evaluation of Platelets: Antimicrobial Treatments and Evaluation of the Treated Products for Functions

Center for Biologics Evaluation and Research (CBER) | Southern Md Facility, Maryland | United States | about 16 hours ago

that research materials and laboratory notebooks are the property of the FDA; ORISE fellow’s obligation to protect and not to further disclose or use non-public information.

FDA Non-clinical Identification and Mitigation of Safety Risks During the Development and Licensure of Protein-therapeutics

Center for Biologics Evaluation and Research (CBER) | Silver Spring, Maryland | United States | 5 days ago

the Guidelines for Non-U.S. Citizens Details page  of the program website for information about the valid immigration statuses that are acceptable for program participation. This program, administered by ORAU

FDA Research Opportunity - Detection of Emerging Pathogens that Threaten Blood Safety

Center for Biologics Evaluation and Research (CBER) | Southern Md Facility, Maryland | United States | about 16 hours ago

that research materials and laboratory notebooks are the property of the FDA; ORISE fellow’s obligation to protect and not to further disclose or use non-public information.

FDA Evaluation and Characterization of Neutralizing Antibodies Against Viruses Relevant to Blood-Derived Products

Center for Biologics Evaluation and Research (CBER) | Silver Spring, Maryland | United States | about 15 hours ago

of the FDA; ORISE fellow’s obligation to protect and not to further disclose or use non-public information.